Hainan General Hospital Lecheng Branch made China's first XOSPATA prescription on Nov 2, 2020.  XOSPATA is the first drug of its kind to be used by Lecheng to treat a patient with acute myelogenous leukemia (AML).

The licensed drug XOSPATA is a global innovative drug introduced for domestic AML patients. It is a second-generation FLT3 inhibitor. Compared with the first-generation drug, it has a better activation structure and specifically binds to FLT3-ITD antibodies, effectively inhibiting the proliferation of leukemia cells, thereby exerting an anti-tumor effect.